Jessica Malachek, APRN
Primary Care · Las Vegas, NVNPI 1346887809
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 41.5% of the total. Reporting peaked in 2021 at $604 and has fallen 97.2% since, to $17 in 2024.
Across 55 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$338
- Novo Nordisk$186
- Biohaven Pharmaceuticals, Inc.$61
- Esperion Therapeutics, Inc.$37
- Mylan Specialty L.p.$35
- Lilly USA, LLC$33
- plus $123 from 6 others
What the payments were for
- Food & beverage$813100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $338 |
| Novo Nordisk | 12 | $186 |
| Biohaven Pharmaceuticals, Inc. | 5 | $61 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Mylan Specialty L.p. | 1 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Genentech USA, Inc. | 5 | $29 |
| Pfizer | 1 | $25 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$813 in reported general payments places this provider in the 70th percentile of 81 primary care providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefdinir | 15 | $380 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 29 | $287 |
| Doxycycline Monohydrate | 15 | $269 |
| Fluticasone Propionate | 31 | $258 |
| Mupirocin | 22 | $156 |
| Ondansetron OdtOndansetron | 14 | $95 |
| Hydrocortisone | 13 | $59 |
| Prednisone | 19 | $36 |
| Meloxicam | 11 | $16 |
Paid to pharmacies, not to this prescriber.
Other primary care in Las Vegas
- Jennifer CribbLas Vegas$7K
- Ruel MarianoLas Vegas$4K
- George Gabriel ToldnessLas Vegas$4K
- Jona SteadLas Vegas$3K
- Mario LuglioLas Vegas$3K
- Jocybel ItorralbaLas Vegas$3K
- Jerifaye FloresLas Vegas$2K
- Sneha ThomasLas Vegas$2K
- Yoslady MoralesLas Vegas$2K
- Christine EspenillaLas Vegas$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.